ZIMBABWE, & HIV and AIDS hit countries, face anti-retroviral drugs crisis as ARV’s will be back on patent and cos tover US$10 000 per year per patient when India stops making generic ARV’s soon

ZIMBABWE, & HIV and AIDS hit countries, face anti-retroviral drugs crisis as ARV’s will be back on patent  and cos tover US$10 000 per year per patient when India stops making generic ARV’s soon

  ZIMBABWE, among other HIV and AIDS hit countries, is staring at a potential dilemma in accessing anti-retroviral drugs as indications are that the drug will be back on patent where it will cost more than $10 000 per year per patient as India will soon stop making generic ARV’s that are cheaper. Zimbabwe was accessing most of its ARVs, for example the Aids triple therapy, at an average of $200 per patient per year but…

Read More